Navigation Links
Catalent Completes Purchase of Pharmaceutical Packaging Facility in Shiga, Japan
Date:7/1/2020

Catalent, a global leader in clinical supply services, today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Operating in partnership with the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both local customers, and global biotech and pharmaceutical companies. The facility will play an important role in Catalent’s expanding Asia-Pacific network, working alongside two sites in China and one in Singapore to ensure customers’ clinical trials are well-served across the region.

The facility will offer extensive clinical supply services including access to Catalent’s FastChain® demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, as well as clinical returns and destruction services.

For more information on Catalent’s clinical supply capabilities visit https://www.clinical.catalent.com.

About Catalent Clinical Supply Services
Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialized supply chain services including direct-to-patient and demand-led supply. With nine GMP clinical packaging facilities and over 50 strategically located depots on six continents combined with more than 25 years’ experience across thousands of studies in more than 80 countries, Catalent has the comprehensive services, global scale and expertise necessary to reliably supply clinical trials of all sizes and complexity anywhere in the world.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including approximately 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_completes_purchase_of_pharmaceutical_packaging_facility_in_shiga_japan/prweb17231096.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
2. Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity
3. Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
4. Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
5. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
6. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
7. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
8. Catalent Receives P&G External Business Partner of the Year Award
9. Lifecycle Biotechnologies Completes Full Integration of Chata Biosystems and VI Plastics
10. Great Point Partners Completes Growth Equity Investment in Axiom Real-Time Metrics
11. Bode Technology Completes DNA Analysis on 100,000 Sexual Assault Kits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2020)... MANSFIELD, Mass. (PRWEB) , ... June 24, 2020 ... ... provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug ... trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. ...
(Date:6/23/2020)... ... , ... The field of quantitation of large molecules or proteins has been ... However, the use of mass spectrometry in this field has gained a lot of ... you choose which approach to use (LBA or MS)?” In many cases, either ...
(Date:6/19/2020)... ... ... The director of stem cell biotechnology company Asymmetrex , Dr. James L. Sherley, ... easier access to stem cell counting, they will soon make it a routine part ... in the U.S., Asymmetrex is offering free tissue stem cell counting at its ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... , ... July 09, 2020 ... ... company, announced today that Massachusetts Institute of Technology (MIT) has expanded the ... license allows PathSensors to move into the point-of-care diagnostic market, focusing initially ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to date growth of 40% in 2020, despite many obstacles created as a ... aims to increase revenue for its partnered medical practices and medical manufacturers by ...
(Date:6/28/2020)... (PRWEB) , ... June 25, 2020 , ... ... to advance photodynamic therapy for treating cancer, today announced the company has entered ... (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen ... will be presented June 22-24 during the American Association for Cancer Research Virtual ... other profiles the potent, consistent single agent activity in KEAP1 mutant tumor models ...
Breaking Biology Technology: